What Can Cause Pfizer Stock To Crash?
Pfizer (PFE) is facing threats. Even the biggest names aren’t invincible. Stocks can drop sharply without warning – wiping out months or years of gains in a matter of weeks. History shows that sudden market swings can hit any company, no matter how dominant it seems.
Pfizer’s shares, after a year of modest gains, recently dipped following a cautious 2026 outlook, underscoring persistent challenges. The pharmaceutical giant faces a formidable patent cliff and waning COVID-19 product demand, projecting future profits below analyst expectations. This shifting sentiment highlights a vulnerability: can pipeline innovations and cost efficiencies truly offset revenue erosion from expiring exclusivities and a post-pandemic recalibration, or will the stock continue to drift?
What Could Send The Stock Crashing?
- Patent Cliff Risk: Pfizer faces a major “LOE wave” with $17-$18 billion in annual revenues at risk by 2028 from drugs like Xeljanz and Eliquis having key patents expire by 2026-2028. Pfizer plans $7.7 billion in cost cuts by 2027 to mitigate this.
- Declining COVID Sales: Projected 2026 COVID-19 product sales are forecast to drop to $5 billion, a $1.5 billion decline from 2025 estimates, significantly impacting Pfizer’s 2026 profit outlook. Non-COVID product operational growth was 4% in Q3 2025.
- Pipeline Execution: Failures like discontinuing the GLP-1R agonist danuglipron in 2025 and two Seagen pipeline assets in November 2025, coupled with the dilutive effect of the Metsera acquisition on 2026 EPS, threaten future growth. Pfizer aims for eight or more oncology blockbusters by 2030.
What’s The Worst That Could Happen?
Looking at Pfizer’s stock through tough times shows risk is still real, even with strong fundamentals. It fell about 39% in the Dot-Com Bubble and dropped more sharply by 53% during the Global Financial Crisis. The 2018 correction and Covid pandemic saw declines close to 24% and 29%, respectively. The inflation shock was especially harsh, with Pfizer tumbling over 53%. So, even with the company’s solid profile, market downturns have hit it hard. Quality matters, but during big sell-offs, few stocks escape significant losses.
Is Risk Showing Up In The Company’s Financials Yet?
Let’s take a look at fundamentals
- Revenue Growth: 3.9% LTM and -13.2% last 3-year average.
- Cash Generation: Nearly 16.5% free cash flow margin and 24.6% operating margin LTM.
- Valuation: Pfizer stock trades at a P/E multiple of 14.7
| PFE | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Pharmaceuticals | – |
| PE Ratio | 14.7 | 23.5 |
|
|
||
| LTM* Revenue Growth | 3.9% | 6.0% |
| 3Y Average Annual Revenue Growth | -13.2% | 5.4% |
|
|
||
| LTM* Operating Margin | 24.6% | 18.8% |
| 3Y Average Operating Margin | 19.4% | 18.3% |
| LTM* Free Cash Flow Margin | 16.5% | 13.4% |
*LTM: Last Twelve Months
If you want more details, read Buy or Sell PFE Stock.
The Right Way To Invest Is Through Portfolios
Individual picks can be volatile but staying invested is what matters. A diversified portfolio helps you stay the course, capture upside and reduce downside
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.